# The Effect of Biktarvy (B/F/TAF) on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers

> **NCT04950530** · PHASE1 · COMPLETED · sponsor: **Chelsea and Westminster NHS Foundation Trust** · enrollment: 25 (actual)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** BIKTARVY 50Mg-200Mg-25Mg Tablet

## Key facts

- **NCT ID:** NCT04950530
- **Lead sponsor:** Chelsea and Westminster NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-22
- **Primary completion:** 2024-02-29
- **Final completion:** 2024-02-29
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2024-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04950530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04950530, "The Effect of Biktarvy (B/F/TAF) on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT04950530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*